MUNSTER, Germany, November 19 MONITORING FORCE GmbHannounced that they have filed on November 16th, 2009 Flibanserin in theindication treatment-relevant levodopa-induced dyskinesia in Parkinson'sdisease for orphan drug status designation with the European Medicines Agency(EMEA). Levodopa-induced dyskinesia is a complication of the mainstaytreatment in advanced Parkinson's and a serious burden to some of thoseaffected, since it may be disabling for the patients and preventing them fromreceiving optimal treatment for Parkinson's.
Flibanserin is a 5-HT1a agonist and a 5-HT2a antagonist and thus fits inwith the current theory on levodopa-induced dysinesia that dyskinesia iscaused by the release of dopamine from serotonergic neurons. MONITORING FORCEis preparing to file another orphan drug status application with the UnitedStates Food and Drug Administration (FDA) and expects the first clinicaltrial in Parkinson's patients to start by mid-2010.
MONITORING FORCE GmbH is a clinical research company based inMunster/Germany with affiliates in the United States, France, Italy and othercountries. MONITORING FORCE does contract research for the pharmaceuticalindustry as well as re-purposing drug development projects on their own.MONITORING FORCE has been founded in Germany in 1995 and spread to othercountries since. Parkinson's disease is a primary focus of the company.Contact (Company): Dr. Jurgen Beck General Manager, MONITORING FORCE GmbH Bahnhofstrasse 111, 48143 Munster, Germany Tel.: +49-251-214-01-30, +49-251-26-39-577 (DD) Fax: +49-251-21-401-53-9, Mobile: +49-171-869-82-40 [email protected]
, http://www.monitoring-force.eu Contact (Media): Aysun Ertan Project Manager, Targa Communications Goethestrasse 22, 60313 Frankfurt am Main, Germany Tel.: +49-69-66-36-83-98, Fax: +49-69-66-36-83-99 [email protected]
SOURCE MONITORING FORCE GmbH